Image Challenge

Main Article Content

Sumapa Chaiamnuay

Abstract

An 80-year-old female with osteoporosis presented to the clinic in September 2026 reporting acute, severe, and spontaneous mid-to-lower back pain. Baseline dual-energy X-ray absorptiometry (DXA) in April 2022 demonstrated a T-score of -3.0 at the femoral neck, -2.8 at the total hip, and -3.2 at the lumbar spine (L1–L4). She had no prior history of fragility fractures. She had received denosumab 60 mg subcutaneously every 6 months for 6 doses between April 2022 and April 2025 (total exposure 7 doses). She was lost to follow-up because she felt well and did not receive her scheduled dose in October 2025 or any subsequent antiresorptive therapy. Approximately 17 months after her last denosumab injection, she developed sudden, debilitating thoracic and lumbar back pain without preceding trauma. Physical examination revealed 3 centimeters of height loss since the April 2025 visit, thoracic spine tenderness, and increased kyphosis compared with prior visits. Thoracolumbar radiographs were obtained (Figures 1 and 2).

Article Details

How to Cite
1.
Chaiamnuay S. Image Challenge. Thai J Rheu [internet]. 2026 Oct. 9 [cited 2026 Oct. 12];3(3):31-6. available from: https://he04.tci-thaijo.org/index.php/tjr/article/view/5285
Section
Quiz

References

McClung MR, Wagman RB, Miller PD, Wang A, Lewiecki EM. Observations following discontinuation of long-term denosumab therapy. Osteoporos Int. 2017;28(5):1723-32.

Kumar S, Wang M, Kim AS, Center JR, McDonald MM, Girgis CM. Denosumab discontinuation in the clinic: implications of rebound bone turnover and emerging strategies to prevent bone loss and fractures. J Bone Miner Res. 2025;40(9):1017-34.

Anastasilakis AD, Polyzos SA, Makras P, Aubry-Rozier B, Kaouri S, Lamy O. Clinical Features of 24 Patients With Rebound-Associated Vertebral Fractures After Denosumab Discontinuation: Systematic Review and Additional Cases. J Bone Miner Res. 2017;32(6):1291-6.

Krikelis M, Gazi S, Trovas G, Makris K, Chronopoulos E, Tournis S. Progression of multiple vertebral fractures after denosumab discontinuation under treatment with romosozumab. A case-report. Joint Bone Spine. 2024;91(5):105754.

Sarli M, Farias V, Abdala R, Armanelli E, Bocci C, Jerkovich F, et al. Romosozumab after rebound vertebral fractures induced by denosumab discontinuation: a case series. JBMR Plus. 2026;10(2):ziaf186.

Tsourdi E, Zillikens MC, Meier C, Body JJ, Gonzalez Rodriguez E, Anastasilakis AD, et al. Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS. J Clin Endocrinol Metab. 2021;106(1):264-81.